Rivastigmine in the treatment of patients with Alzheimer’s disease

References

• AlvaGPotkinSG2003Alzheimer disease and other dementiasClin Geriatr Med197637615024811
   PubMed Web of Science ®Google Scholar
• BelleSHZhangSCzajaSJ2004Use of cognitive enhancement medication in persons with Alzheimer disease who have a family caregiver: results from the Resources for Enhancing Alzheimer’s Caregiver Health (REACH) projectAm J Geriatr Psychiatry12250715126225
   PubMed Web of Science ®Google Scholar
• BlennowKde LeonMJZetterbergH2006Alzheimer’s diseaseLancet36838740316876668
   PubMed Web of Science ®Google Scholar
• BlountPJNguyenCDMcDeavittJT2002Clinical use of cholinomimetic agents: a reviewJ Head Trauma Rehabil173142112106000
   PubMed Web of Science ®Google Scholar
• BohnenNKauferDHendricksonR2004Effects of donepezil on motor function in patients with Alzheimer diseaseJ Clin Psychopharmacol24354615118497
   PubMed Web of Science ®Google Scholar
• BonnerLTPeskindER2002Pharmacologic treatments of dementiaMed Clin North Am866577412171061
   PubMed Web of Science ®Google Scholar
• BullockRTouchonJBergmanH2005Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year periodCurr Med Res Opin2113172716083542
   PubMed Web of Science ®Google Scholar
• CleggABryantJNicholsonT2002Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease. A systematic reviewInt J Technol Assess Health Care1849750712391943
   PubMed Web of Science ®Google Scholar
• Corey-BloomJAnandRVeachJfor the ENA 713 B352 Study1998A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s diseaseInt J Geriatr Psychopharmacol15565
   Google Scholar
• CummingsJL2000Cholinesterase inhibitors: expanding applicationsLancet3562024511145482
   PubMed Web of Science ®Google Scholar
• CummingsJL2005Behavioral and neuropsychiatric outcomes in Alzheimer’s diseaseCNS Spectr10Suppl 1822516273027
   PubMed Web of Science ®Google Scholar
• Darreh-ShoriTAlmkvistOGuanZZ2002Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 monthsNeurology5945637212196650
   PubMed Web of Science ®Google Scholar
• Darreh-ShoriTHellstrom-LindahlEFlores-FloresC2004Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer’s disease patientsJ Neurochem88511021315009666
   PubMed Web of Science ®Google Scholar
• DarveshSHopkinsDAGeulaC2003Neurobiology of butyrylcholinesteraseNat Rev Neurosci4131812563284
   PubMed Web of Science ®Google Scholar
• Di LazzaroVOlivieroAPilatoF2004Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer’s diseaseJ Neurol Neurosurg Psychiatry75555915026495
   PubMed Web of Science ®Google Scholar
• EmreM2004Dementia in Parkinson’s disease:cause and treatmentCurr Opin Neurol17439940415247534
   PubMed Web of Science ®Google Scholar
• ErkinjunttiTSkoogILaneR2002Rivastigmine in patients with Alzheimer’s disease and concurrent hypertensionInt J Clin Pract5610791612510954
   PubMed Web of Science ®Google Scholar
• EskanderMFNagykeryNGLeungEY2005Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer’s plaques and tanglesBrain Res10601445216212945
   PubMed Web of Science ®Google Scholar
• FactorSAFriedmanJHLannonMC2001Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease:results of the 12 week open label extension in the PSYCLOPS trialMov Disord16135911215574
   PubMed Web of Science ®Google Scholar
• FarlowMAnandRMessinaJJr2000A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s diseaseEur Neurol442364111096224
   PubMed Web of Science ®Google Scholar
• FarlowMPotkinSKoumarasB2003Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trialArch Neurol60843812810489
   PubMed Web of Science ®Google Scholar
• FarlowMR2002Do cholinesterase inhibitors slow progression of Alzheimer’s disease?Int J Clin PractSuppl3744
   Google Scholar
• FarlowMRHakeAMessinaJ2001Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progressionArch Neurol584172211255445
   PubMed Web of Science ®Google Scholar
• FarlowMRLillyML2005Rivastigmine:an open-label, observational study of safety and effectiveness in treating patients with Alzheimer’s disease for up to 5 yearsBMC Geriatr5315659242
   PubMedGoogle Scholar
• ForetteFAnandRGharabawiG1999A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon)Eur J Neurol6423910362894
   PubMed Web of Science ®Google Scholar
• FrankfortSVAppelsBAde BoerA2005Discontinuation of rivastigmine in routine clinical practiceInt J Geriatr Psychiatry2011677116315150
   PubMed Web of Science ®Google Scholar
• FrankfortSVAppelsBAde BoerA2006Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer’s disease in an outpatient geriatric settingInt J Clin Pract606465416805746
   PubMed Web of Science ®Google Scholar
• GiacobiniE2000Cholinesterase inhibitors stabilize Alzheimer’s diseaseAnn NY Acad Sci920321711193171
   PubMed Web of Science ®Google Scholar
• GiladiNShabtaiHGurevichT2003Rivastigmine (Exelon) for dementia in patients with Parkinson’s diseaseActa Neurol Scand1083687314616309
   PubMed Web of Science ®Google Scholar
• GillSSBronskillSEMamdaniM2004Representation of patients with dementia in clinical trials of donepezilCan J Clin Pharmacol11e274e8515604527
   PubMedGoogle Scholar
• GreigNHLahiriDKSambamurtiK2002Butyrylcholinesterase:an important new target in Alzheimer’s disease therapyInt Psychogeriatr14Suppl 1779112636181
   PubMed Web of Science ®Google Scholar
• HegerlUMerglRHenkelV2003Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementiaJ Clin Psychopharmacol232141612640228
   PubMed Web of Science ®Google Scholar
• HeinzeMAndreaeDGrohmannR2002Rivastigmin and impaired motor functionPharmacopsychiatry35798011951151
   PubMed Web of Science ®Google Scholar
• IoffeME2004Brain mechanisms for the formation of new movements during learning:the evolution of classical conceptsNeurosci Behav Physiol3451815109077
   PubMedGoogle Scholar
• JeffersonALCosentinoSABallSK2002Errors produced on the mini-mental state examination and neuropsychological test performance in Alzheimer’s disease, ischemic vascular dementia, and Parkinson’s diseaseJ Neuropsychiatry Clin Neurosci143112012154156
   PubMed Web of Science ®Google Scholar
• JuncosJLRobertsVJEvattML2004Quetiapine improves psychotic symptoms and cognition in Parkinson’s diseaseMov Disord19293514743357
   PubMed Web of Science ®Google Scholar
• KurzAFarlowMQuargP2004Disease stage in Alzheimer disease and treatment effects of rivastigmineAlzheimer Dis Assoc Disord18123815494617
   PubMed Web of Science ®Google Scholar
• LeroiIBrandtJReichSG2004Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s diseaseInt J Geriatr Psychiatry191814716693
   PubMed Web of Science ®Google Scholar
• LiepertJBarKJMeskeU2001Motor cortex disinhibition in Alzheimer’s diseaseClin Neurophysiol11214364111459683
   PubMed Web of Science ®Google Scholar
• MathesonAJLambHM2000Quetiapine–A review of its clinical potential in the management of psychotic symptoms in Parkinson’s diseaseCNS Drugs1415772
   Web of Science ®Google Scholar
• MerimsDShabtaiHKorczynAD2004Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s diseaseJ Neural Transm11114475315480845
   PubMed Web of Science ®Google Scholar
• MorganteLEpifanioASpinaE2004Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosisClin Neuropharmacol27153615319699
   PubMed Web of Science ®Google Scholar
• MuhlackSPrzuntekHMüllerT2006Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer’s diseasePharmacopsychiatry39161916453249
   PubMed Web of Science ®Google Scholar
• MüllerTKuhnWSchulteT2003aIntravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson’s diseaseNeurosci Lett33925812618292
   PubMed Web of Science ®Google Scholar
• MüllerTMeiselMRussH2003bMotor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson’s disease patientsJ Neurol Sci21361512873756
   PubMed Web of Science ®Google Scholar
• MüllerTSchaferSKuhnW2000Correlation between tapping and inserting of pegs in Parkinson’s diseaseCan J Neurol Sci273111511097522
   PubMed Web of Science ®Google Scholar
• PalPKLeeCSSamiiA2001Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson’s disease and correlates with PETParkinsonism Relat Disord7305911344014
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group1999Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s diseaseN Engl J Med3407576310072410
   PubMed Web of Science ®Google Scholar
• PoeweWWoltersEEmreM2006Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease:an active treatment extension studyMov Disord214566116229010
   PubMed Web of Science ®Google Scholar
• PolinskyRJ1998Clinical pharmacology of rivastigmine:a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s diseaseClin Ther20634479737824
   PubMed Web of Science ®Google Scholar
• PrianoLGascoMRMauroA2006Transdermal treatment options for neurological disorders:impact on the elderlyDrugs Aging233577516823990
   PubMed Web of Science ®Google Scholar
• RichardIHJustusAWGreigNH2002Worsening of motor function and mood in a patient with Parkinson’s disease after pharmacologic challenge with oral rivastigmineClin Neuropharmacol25296912469000
   PubMed Web of Science ®Google Scholar
• RitchieCWAmesDClaytonT2004Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer diseaseAm J Geriatr Psychiatry123586915249273
   PubMed Web of Science ®Google Scholar
• RoslerMAnandRCicin-SainA1999Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trialBMJ318633810066203
   PubMed Web of Science ®Google Scholar
• SaftCAndrichJMeiselNM2003Assessment of complex movements reflects dysfunction in Huntington’s diseaseJ Neurol25014697414673581
   PubMed Web of Science ®Google Scholar
• SaftCAndrichJMeiselNM2004Congruent deterioration of complex and simple movements in patients with Huntington’s diseaseJ Neural TransmSuppl9710415599608
   PubMed Web of Science ®Google Scholar
• SpencerCMNobleS1998Rivastigmine. A review of its use in Alzheimer’s diseaseDrugs Aging133914119829166
   PubMed Web of Science ®Google Scholar
• TakedaALovemanECleggA2006A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s diseaseInt J Geriatr Psychiatry21172816323253
   PubMed Web of Science ®Google Scholar
• TariotPN2001Maintaining cognitive function in Alzheimer disease: how effective are current treatments?Alzheimer Dis Assoc Disord15Suppl 1S26S3311669506
   PubMed Web of Science ®Google Scholar
• TiraboschiPHansenLAAlfordM2000Cholinergic dysfunction in diseases with Lewy bodiesNeurology544071110668703
   PubMed Web of Science ®Google Scholar
• van DyckCH2004Understanding the latest advances in pharmacologic interventions for Alzheimer’s diseaseCNS Spectr9Suppl 524815241297
   PubMed Web of Science ®Google Scholar
• Van HiltenJJMiddelkoopHAKuiperSI1993Where to record motor activity:an evaluation of commonly used sites of placement for activity monitorsElectroencephalogr Clin Neurophysiol89359627691576
   PubMedGoogle Scholar
• van VugtJPSieslingSPietKK2001Quantitative assessment of daytime motor activity provides a responsive measure of functional decline in patients with Huntington’s diseaseMov Disord16481811391742
   PubMed Web of Science ®Google Scholar
• WeinstockM1999Selectivity of cholinesterase inhibition–Clinical implications for the treatment of Alzheimer’s diseaseCNS Drugs1230723
   Web of Science ®Google Scholar
• WerberEARabeyJM2001The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson’s disease and dementiaJ Neural Transm10813192511768630
   PubMed Web of Science ®Google Scholar
• WilkinsonDGFrancisPTSchwamE2004Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacyDrugs Aging214537815132713
   PubMed Web of Science ®Google Scholar
• WilkinsonDGPassmoreAPBullockR2002A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s diseaseInt J Clin Pract56441612166542
   PubMed Web of Science ®Google Scholar
• WinbladBBeusterienKMThomasSK2006Caregivers prefer patches to capsules: results from a 24-week placebo-controlled study of rivastigmine (IDEAL trial)Hot topic session ICAD 2006
   Google Scholar